| 1. |
- Auer, Florian, et al.
(författare)
-
Controlled experimentation in continuous experimentation : Knowledge and challenges
- 2021
-
Ingår i: Information and Software Technology. - : Elsevier B.V.. - 0950-5849 .- 1873-6025. ; 134
-
Tidskriftsartikel (refereegranskat)abstract
- Context: Continuous experimentation and A/B testing is an established industry practice that has been researched for more than 10 years. Our aim is to synthesize the conducted research. Objective: We wanted to find the core constituents of a framework for continuous experimentation and the solutions that are applied within the field. Finally, we were interested in the challenges and benefits reported of continuous experimentation. Methods: We applied forward snowballing on a known set of papers and identified a total of 128 relevant papers. Based on this set of papers we performed two qualitative narrative syntheses and a thematic synthesis to answer the research questions. Results: The framework constituents for continuous experimentation include experimentation processes as well as supportive technical and organizational infrastructure. The solutions found in the literature were synthesized to nine themes, e.g. experiment design, automated experiments, or metric specification. Concerning the challenges of continuous experimentation, the analysis identified cultural, organizational, business, technical, statistical, ethical, and domain-specific challenges. Further, the study concludes that the benefits of experimentation are mostly implicit in the studies. Conclusion: The research on continuous experimentation has yielded a large body of knowledge on experimentation. The synthesis of published research presented within include recommended infrastructure and experimentation process models, guidelines to mitigate the identified challenges, and what problems the various published solutions solve. © 2021 The Authors
|
|
| 2. |
- Auer, Florian, et al.
(författare)
-
From monolithic systems to Microservices : An assessment framework
- 2021
-
Ingår i: Information and Software Technology. - : Elsevier B.V.. - 0950-5849 .- 1873-6025. ; 137
-
Tidskriftsartikel (refereegranskat)abstract
- Context: Re-architecting monolithic systems with Microservices-based architecture is a common trend. Various companies are migrating to Microservices for different reasons. However, making such an important decision like re-architecting an entire system must be based on real facts and not only on gut feelings. Objective: The goal of this work is to propose an evidence-based decision support framework for companies that need to migrate to Microservices, based on the analysis of a set of characteristics and metrics they should collect before re-architecting their monolithic system. Method: We conducted a survey done in the form of interviews with professionals to derive the assessment framework based on Grounded Theory. Results: We identified a set consisting of information and metrics that companies can use to decide whether to migrate to Microservices or not. The proposed assessment framework, based on the aforementioned metrics, could be useful for companies if they need to migrate to Microservices and do not want to run the risk of failing to consider some important information. © 2021 The Author(s)
|
|
| 3. |
- Auer, Florian, et al.
(författare)
-
Towards defining a microservice migration framework
- 2018
-
Ingår i: ACM International Conference Proceeding Series. - New York, NY, USA : Association for Computing Machinery.
-
Konferensbidrag (refereegranskat)abstract
- Microservices are more and more popular. As a result, some companies started to believe that microservices are the solution to all of their problems and rush to adopt microservices without sufficient knowledge about the impacts. Most of the time they expect to decrease their maintenance effort or to ease the deployment process. However, re-architecting a system to microservices is not always beneficial. In this work we propose a work-plan to identify a decision framework that supports practitioners in the understanding of possible migration based benefits and issues. This will lead to more reasoned decisions and mitigate the risk of migration. © 2018 Copyright held by the owner/author(s).
|
|
| 4. |
- Bachelet, Delphine, et al.
(författare)
-
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis : A Collaborative Cohort Analysis
- 2016
-
Ingår i: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 11:11
-
Tidskriftsartikel (refereegranskat)abstract
- Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations between anti-drug antibody (ADA) occurrence and demographic and clinical factors. Retrospective data from routine ADA test laboratories in Sweden, Denmark, Austria and Germany (Dusseldorf group) and from one research study in Germany (Munich group) were gathered to build a collaborative multi-cohort dataset within the framework of the ABIRISK project. A subset of 5638 interferon-beta (IFN beta)-treated and 3440 natalizumab-treated patients having data on at least the first two years of treatment were eligible for interval-censored time-to-event analysis. In multivariate Cox regression, IFN beta-1a subcutaneous and IFN beta-1b subcutaneous treated patients were at higher risk of ADA occurrence compared to IFN beta-1a intramuscular-treated patients (pooled HR = 6.4, 95% CI 4.9-8.4 and pooled HR = 8.7, 95% CI 6.6-11.4 respectively). Patients older than 50 years at start of IFN beta therapy developed ADA more frequently than adult patients younger than 30 (pooled HR = 1.8, 95% CI 1.4-2.3). Men developed ADA more frequently than women (pooled HR = 1.3, 95% CI 1.1-1.6). Interestingly we observed that in Sweden and Germany, patients who started IFN beta in April were at higher risk of developing ADA (HR = 1.6, 95% CI 1.1-2.4 and HR = 2.4, 95% CI 1.5-3.9 respectively). This result is not confirmed in the other cohorts and warrants further investigations. Concerning natalizumab, patients older than 45 years had a higher ADA rate (pooled HR = 1.4, 95% CI 1.0-1.8) and women developed ADA more frequently than men (pooled HR = 1.4, 95% CI 1.0-2.0). We confirmed previously reported differences in immunogenicity of the different types of IFN beta. Differences in ADA occurrence by sex and age are reported here for the first time. These findings should be further investigated taking into account other exposures and biomarkers.
|
|
| 5. |
- Jensen, Poul Erik H., et al.
(författare)
-
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis : Results from the ABIRISK prospective cohort study
- 2019
-
Ingår i: Journal of Neuroimmunology. - : Elsevier. - 0165-5728 .- 1872-8421. ; 326, s. 19-27
-
Tidskriftsartikel (refereegranskat)abstract
- Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.
|
|
| 6. |
- Link, Jenny, et al.
(författare)
-
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe : A descriptive study of test results
- 2017
-
Ingår i: PLOS ONE. - : Public Library of Science. - 1932-6203. ; 12:2
-
Tidskriftsartikel (refereegranskat)abstract
- Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several European countries. ADA data generated in Europe during the more than 10 years of ADA monitoring in MS patients treated with interferon beta (IFN beta) and natalizumab have been pooled and characterized through collaboration within a European consortium. The aim of this study was to report on the clinical practice of ADA testing in Europe, considering the number of ADA tests performed and type of ADA assays used, and to determine the frequency of ADA testing against the different drug preparations in different countries. A common database platform (tranSMART) for querying, analyzing and storing retrospective data of MS cohorts was set up to harmonize the data and compare results of ADA tests between different countries. Retrospective data from six countries (Sweden, Austria, Spain, Switzerland, Germany and Denmark) on 20,695 patients and on 42,555 samples were loaded into tranSMART including data points of age, gender, treatment, samples, and ADA results. The previously observed immunogenic difference among the four IFN beta preparations was confirmed in this large dataset. Decreased usage of the more immunogenic preparations IFN beta-1a subcutaneous (s.c.) and IFN beta-1b s.c. in favor of the least immunogenic preparation IFN beta-1a intramuscular (i.m.) was observed. The median time from treatment start to first ADA test correlated with time to first positive test. Shorter times were observed for IFN beta-1b-Extavia s. c. (0.99 and 0.94 years) and natalizumab (0.25 and 0.23 years), which were introduced on the market when ADA testing was already available, as compared to IFN beta-1a i. m. (1.41 and 2.27 years), IFN beta-1b-Betaferon s. c. (2.51 and 1.96 years) and IFN beta-1a s. c. (2.11 and 2.09 years) which were available years before routine testing began. A higher rate of anti-IFN beta ADA was observed in test samples taken from older patients. Testing for ADA varies between different European countries and is highly dependent on the policy within each country. For drugs where routine monitoring of ADA is not in place, there is a risk that some patients remain on treatment for several years despite ADA positivity. For drugs where a strategy of ADA testing is introduced with the release of the drug, there is a reduced risk of having ADA positive patients and thus of less efficient treatment. This indicates that potential savings in health cost might be achieved by routine analysis of ADA.
|
|
| 7. |
- Svensson, Tommy, 1970, et al.
(författare)
-
CELTIC CP5-026 WINNER+, D1.9 Final Innovation Report
- 2010
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- This deliverable is the final innovation report from the innovation workpackage in WINNER+. The document describes the latest innovations and their assessment as well as summarizes the innovations developed in the work package during the project. We analyze the suitability of these innovations as technology enablers for improving current systems, in particular IMT Advanced and beyond.
|
|
